Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. News
  7. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 100 million in funding from Jiangsu Hengrui Medicine Co., Ltd.

08/25/2021 EST

Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it has entered into a capital increase and shareholding agreement for a private placement of common shares for gross proceeds of CNY 100 million on August 25, 2021. The transaction will include participation from Jiangsu Hengrui Medicine Co., Ltd. As a result, the investor will own more than 2.5% stake in the company. The transaction does not need to be submitted to the investor's board of directors and shareholders' meeting for deliberation. The transaction still needs the approval of relevant government departments.


ę S&P Capital IQ 2021
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
2021CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater C..
MT
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended S..
CI
2021BeyondSpring Shares Up 17% After China Commercialization Deal
DJ
2021Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1..
CI
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended Jun..
CI
2021MARKET CHATTER : China Adds New Drugs to Cover Under Health Insurance Program
MT
2021China stocks slip as healthcare firms retreat; Hong Kong up
RE
2021Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announces on Obtaining Notice of Approval of ..
CI
2021Shanghai Fosun Pharmaceutical's H-Shares Surge to All-Time High
DJ
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended..
CI
More news
Financials
Sales 2021 29 321 M 4 607 M 4 607 M
Net income 2021 6 646 M 1 044 M 1 044 M
Net cash 2021 18 323 M 2 879 M 2 879 M
P/E ratio 2021 37,3x
Yield 2021 0,47%
Capitalization 262 B 41 130 M 41 133 M
EV / Sales 2021 8,30x
EV / Sales 2022 7,37x
Nbr of Employees 28 903
Free-Float 46,5%
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 41,09 CNY
Average target price 69,56 CNY
Spread / Average Target 69,3%
EPS Revisions
Managers and Directors
Wei Dong Chairman-Supervisory Board
Piao Yang Sun Chairman
Shuang Xue Independent Director
Qian Wang Independent Director
Jia Hong Dong Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.-18.97%42 423
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642